Engineered Venture Services Finds Vitanova Biomedical to be a Great Investment in the Cancer Drugs Market

In addition to serving a wide, unmet, healthcare need and—of course—addressing the ongoing humanitarian crisis that is cancer, we believe that Vitanova Biomedical has the proper foundation to become a unique, yet financially viable investment opportunity for investors.

Engineered Venture Services (EVS) finds Vitanova Biomedical to be a great investment in the cancer drugs market. This finding is after due diligence research. The company is still an early stage biotech company, with a proprietary cancer killing treatment. It is seeking seed-funding and is a part of a steadily growing $100 billion industry – in the market of “cancer drugs”. Julio Gonzalez, CEO of Engineered Venture Services, supports Vitanova Biomedical’s cause and held a luncheon for guests to find out more about the company’s mission. You can hear Vitanova’s plan in an interview by Ann Vandersteel with Matthew Gdovin, Chief Science Officer of Vitanova Biomedical here.

“Vitanova achieved a high overall rating and scored in the top quartile of Engineered Venture Services’ life sciences ventures; this is primarily due to the dynamic and strength of their management team. EVS finds that it is crucial for these types of companies to not only possess leaders with scientific and technical expertise, but to also put leaders in to place who demonstrate an adeptness in financial literacy and who are business savvy. Vitanova’s management team reflects this dichotomy. In addition to serving a wide, unmet, healthcare need and—of course—addressing the ongoing humanitarian crisis that is cancer, we believe that Vitanova Biomedical has the proper foundation to become a unique, yet financially viable investment opportunity for investors,” said Cat…

Read the full article from the Source…

Leave a Reply

Your email address will not be published. Required fields are marked *